Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zheran,Liu

第一单位： Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

作者： Zheran,Liu ^[1] ; Ye,Chen ^[2] ; Zhigong,Wei ^[1] ; Yan,He ^[1] ; Jingjing,Wang ^[1] ; Xiaoli,Mu ^[1] ; Ling,He ^[1] ; Ruidan,Li ^[1] ; Xiaolin,Hu ^[3] ; Xingchen,Peng ^[4]

作者单位： Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. ^[1] 2 Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China. ^[2] Department of Nursing, West China Hospital, Sichuan University, Chengdu, China. huxiaolin1220@126.com. ^[3] Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. pxx2014@scu.edu. ^[4]

关键词 Metastatic renal cell carcinoma (mRCC)immunotherapy meta-analysis prognosis

主题词贝叶斯定理(Bayes Theorem);癌, 肾细胞(Carcinoma, Renal Cell);人类(Humans);免疫疗法(Immunotherapy);肾肿瘤(Kidney Neoplasms)

DOI 10.21037/apm-20-1884

PMID 33615806

发布时间 2021-05-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交